Caliper LS Introduces Staccato Protein Workstation for Automated Protein Sample Preparation and Analysis
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Caliper Life Sciences, Inc. has launched the Staccato Protein Workstation to specifically address bottlenecks in the characterization of biological therapeutics and biogenerics.
With a goal of assuring the quality of therapeutic proteins and monoclonal antibodies, as well as creating mechanisms for approval of follow-on protein products (biosimilars), the FDA has encouraged the industry to submit biological new drug applications that include quality by design (QbD) parameters.
QbD approaches require multivariate experimentation techniques that generate large numbers of samples and create bottlenecks in sample preparation and analysis.
The Staccato Protein Workstation, developed by Caliper’s Automation, Consulting, Engineering, and Services (ACES) group, incorporates the Sciclone ALH 3000 for automated liquid handling, Twister II for microplate handling, LabChip GXII for microfluidic protein characterization, and various accessories for complete workflow automation.
The LabChip GXII is Caliper’s high throughput system for analyzing protein size, concentration, and purity and serves as a replacement for traditional polyacrylamide gel lectrophoresis (PAGE).
Since its launch in July, 2008, the LabChip GXII platform has been widely adopted by high throughput protein analysis laboratories including companies such as Eli Lilly, GSK Biologics, Merck and Novartis; government and academic institutions such as Howard Hughes Medical Institute, Karlshrue Institute of Technology, National Cancer Institute, Sandia National Laboratories, and University of Queensland; and biotechnology companies such as Amgen, ICx Biosystems, and XcellereX.
With a goal of assuring the quality of therapeutic proteins and monoclonal antibodies, as well as creating mechanisms for approval of follow-on protein products (biosimilars), the FDA has encouraged the industry to submit biological new drug applications that include quality by design (QbD) parameters.
QbD approaches require multivariate experimentation techniques that generate large numbers of samples and create bottlenecks in sample preparation and analysis.
The Staccato Protein Workstation, developed by Caliper’s Automation, Consulting, Engineering, and Services (ACES) group, incorporates the Sciclone ALH 3000 for automated liquid handling, Twister II for microplate handling, LabChip GXII for microfluidic protein characterization, and various accessories for complete workflow automation.
The LabChip GXII is Caliper’s high throughput system for analyzing protein size, concentration, and purity and serves as a replacement for traditional polyacrylamide gel lectrophoresis (PAGE).
Since its launch in July, 2008, the LabChip GXII platform has been widely adopted by high throughput protein analysis laboratories including companies such as Eli Lilly, GSK Biologics, Merck and Novartis; government and academic institutions such as Howard Hughes Medical Institute, Karlshrue Institute of Technology, National Cancer Institute, Sandia National Laboratories, and University of Queensland; and biotechnology companies such as Amgen, ICx Biosystems, and XcellereX.
